IgG4-related ophthalmic disease

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Retrieved on: 
Monday, September 27, 2021
Technology, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Software, Biotechnology, Hardware, Health, Optical, Geographic atrophy, Business development, Ciliary muscle, Diffuse axonal injury, Neuro, Pulse generator, Solution, European Medicines Agency, IgG4-related ophthalmic disease, Inflammation, DNA, Device, AMD, Patient, Diabetic retinopathy, Electroporation, NIU, Pulse, Business, Eye, Risk management, Plasmid, VEGF, Retinitis pigmentosa, History, Glaucoma, RF, EMA, Pharmaceutical industry, Vaccine, Medical device, Eyevensys, Minnetronix Medical, EYEVENSYS, MINNETRONIX MEDICAL

Alan Wirbisky, Director of Device Development at Eyevensys, said: The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess.

Key Points: 
  • Alan Wirbisky, Director of Device Development at Eyevensys, said: The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess.
  • During our 25 year history, we have successfully partnered with many medical startups like Eyevensys to navigate the pitfalls of electromechanical medical device development.
  • Since 1996, Minnetronix Medical has accelerated medical device breakthroughs via design, development and manufacturing services for companies around the world.
  • Minnetronix Medical is based in St. Paul, Minn. More information can be found on the Minnetronix website, by calling 651-917-4060 or emailing [email protected] .

Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

Retrieved on: 
Monday, September 20, 2021
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Irritation, Rosacea, Duane syndrome, Exocrine gland, Glaucoma surgery, Security (finance), IgG4-related ophthalmic disease, Hidradenitis suppurativa, Inflammation, Acetylcholinesterase, Ocular rosacea, Retina, U.S. Securities and Exchange Commission, Patient, GKOS, Cross-link, Corporation, Blepharitis, MIGS, Ophthalmology, Atopic dermatitis, Technology, Research, Parasitism, Dermatology, Safety, Glaucoma, NYSE, Cornea, Skin, Acne, Pharmaceutical industry, Attillaps, Glaukos, ATTILLAPS, GLAUKOS

Demodex-driven meibomian gland dysfunction is characterized by decreased lipid secretion into the tear film and is a leading cause of dry eye disease.

Key Points: 
  • Demodex-driven meibomian gland dysfunction is characterized by decreased lipid secretion into the tear film and is a leading cause of dry eye disease.
  • Under the agreement, Glaukos has the exclusive global right to research, develop, manufacture and commercialize products using certain acetylcholinesterase (AChE) inhibitors for the treatment of ophthalmic diseases caused by Demodex mites.
  • Attillaps lead compounds have demonstrated promising in-vitro results in preclinical settings.
  • This licensing agreement adds a promising therapeutic class that expands the focus of our emerging Corneal Health franchise into new and globally underserved disease indications, said Thomas Burns, Glaukos president and chief executive officer.

Stealth BioTherapeutics to Showcase Leadership in Retinal Mitochondrial Health with Clinical Updates at Ophthalmic Conferences

Retrieved on: 
Tuesday, September 14, 2021
Friedreich's ataxia, American Academy of Ophthalmology, Barth syndrome, Pathology, Drusen, 2021 Essex County Council election, Patient, Heart, American Academy, OCT, Safety, Efficacy, Stealth, Health, Geography, Society, Natural history, Lists of diseases, Degenerative disease, Disease, ASRS, AAO, Association, IgG4-related ophthalmic disease, Pharmacokinetics, DNA, Leber's hereditary optic neuropathy, Duchenne muscular dystrophy, Brain, Elamipretide, Eye, GA, AMD, Geographic atrophy, Pharmaceutical industry, Animal, Environmental remediation, Medical imaging

"GA is a progressively blinding disease which contributes to a loss of independence for affected individuals," said Chief Executive Officer Reenie McCarthy.

Key Points: 
  • "GA is a progressively blinding disease which contributes to a loss of independence for affected individuals," said Chief Executive Officer Reenie McCarthy.
  • Secondary functional endpoints are change in low-luminance reading acuity and best-corrected visual acuity (BCVA), as well as patient-reported assessments of visual quality of life.
  • The data showed improvements from baseline in LLVA and BCVA for patients with GA and drusen who completed the trial.
  • We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction.

CRISPR Based Therapeutics Market Trends and Global Forecasts 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 9, 2021
General Health, Health, Oncology

The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The "CRISPR Based Therapeutics Market, 2021-2030" report features an extensive study of the current market landscape and future opportunity for the players involved in the development of CRISPR based therapeutics for the treatment of a variety of disease conditions.
  • One of the key objectives of the report was to estimate the future growth potential of CRISPR based therapeutics market, over the coming decade.
  • It also includes information on the completed, ongoing and planned clinical trials for CRISPR based therapeutics, sponsored by various industry players.

EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Thursday, September 9, 2021

The presentation will be available on-demand through the H.C. Wainwright conference portal , starting at 7:00 a.m.

Key Points: 
  • The presentation will be available on-demand through the H.C. Wainwright conference portal , starting at 7:00 a.m.
  • EyeGate is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases.
  • EyeGates results may also be affected by factors of which EyeGate is not currently aware.
  • The forward-looking statements in this press release speak only as of the date of this press release.

EQS-News: Kinarus Secures CHF 57 Million Capital Commitment

Retrieved on: 
Thursday, September 9, 2021

Kinarus AG, a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS (GEM), a Luxembourg-based private, alternative investment group, for a CHF 57 million capital commitment.

Key Points: 
  • Kinarus AG, a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS (GEM), a Luxembourg-based private, alternative investment group, for a CHF 57 million capital commitment.
  • Under the agreement, GEM commits to providing Kinarus with a share subscription facility of up to CHF 57 million for a 36-month term following the public listing of Kinarus' shares.
  • Kinarus will always control the timing and, within certain limits, the amount of each individual drawdown under this facility.
  • Concurrent with a public listing of Kinarus after the planned reverse takeover with Perfect Holding, the company will issue warrants to GEM to purchase shares of Kinarus.

EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Retrieved on: 
Wednesday, September 8, 2021

WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) --  EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed target enrollment of 21 patients in the Phase 2 proof-of-concept (“POC”) study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase (“DHODH”) and is first-in-class for ophthalmology indications.

Key Points: 
  • PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase (DHODH) and is first-in-class for ophthalmology indications.
  • The randomized, double-masked, placebo-controlled POC study conducted at a site in Vienna, Austria is designed to evaluate the safety, tolerability, and efficacy of PP-001 in patients with ocular surface inflammation due to dry eye disease.
  • In this study, a total of 21 patients are treated for 12 days with 0.15% of PP-001 or placebo.
  • In addition, EyeGate is developing Ocular Bandage Gel (OBG), a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity.

Stealth BioTherapeutics to Present at Upcoming September Virtual Investor Conferences

Retrieved on: 
Tuesday, September 7, 2021

BOSTON, Sept. 7, 2021 /PRNewswire/ --Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at two upcoming virtual investor conferences in September:

Key Points: 
  • BOSTON, Sept. 7, 2021 /PRNewswire/ --Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at two upcoming virtual investor conferences in September:
    H.C. Wainwright 23rd Annual Global Investment Conference.Pre-recorded presentation available for on-demand viewing starting on Monday, September 13 at 7:00 a.m.
  • Cantor Global Healthcare Conference.Fireside chat on Thursday, September 30 at 11:20 a.m.
  • A live audio webcast of the presentations will be available on the Investors & News section of Stealth's website at https://investor.stealthbt.com/ .
  • We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction.

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, September 1, 2021
Financial compensation, GLOBE, Research, Nasdaq, PDUFA, Food, Oyster Point, IgG4-related ophthalmic disease, NDA, Prescription Drug User Fee Act, Board, Patient, Duane syndrome, Varenicline, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.

Key Points: 
  • Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • Oyster Point Pharmas lead clinical program is focused on the development of OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, being developed as a preservative-free nasal spray to treat the signs and symptoms of dry eye disease and neurotrophic keratopathy.
  • In December 2020, Oyster Point submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease.
  • Oyster Point continues to expand its research and development pipeline through internal innovation and external collaborations with a goal to bring transformative therapies to patients and the eye care providers that take care of them.

Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome

Retrieved on: 
Tuesday, August 24, 2021
Exercise intolerance, Company, Life expectancy, EMA, U.S. Securities and Exchange Commission, Human, Degenerative disease, Leber's hereditary optic neuropathy, SEC, Infection, Friedreich's ataxia, Security (finance), Duchenne muscular dystrophy, DNA, Hope, Nasdaq, Private Securities Litigation Reform Act, Food, Disease, Risk, IgG4-related ophthalmic disease, Marketing, NDA, Heart, Forward-looking statement, Lists of diseases, Review, Clinical trial, File, Elamipretide, Stealth, Safety, Patient, Eye, Barth syndrome, FDA, Heart failure, Brain, Annual report, COVID-19, Muscle weakness, Patent, Protalix BioTherapeutics, Drug development, Pharmaceutical industry

"We initiated our Barth syndrome development efforts at the request of the Barth syndrome community.

Key Points: 
  • "We initiated our Barth syndrome development efforts at the request of the Barth syndrome community.
  • Stealth believes, however, that the data could support an NDA review, and has accordingly submitted the NDA as requested by the Barth syndrome patient community.
  • Elamipretide was previously granted rare pediatric designation, fast track designation, and orphan drug designation by the FDA, and orphan drug designation by the EMA, for the treatment of Barth Syndrome.
  • Barth syndrome occurs almost exclusively in males and is estimated to affect one in 200,000 to 400,000 individuals worldwide.